Ilan Seth Weisberg, MD

Highlights

1
Journal of viral hepatitis · 2022
ISIlan Seth Weisberg
PMID: 36458863DOISenior author40 citations
2
European journal of gastroenterology & hepatology · 2020
ISIlan Seth Weisberg
PMID: 31834054DOISenior author12 citations
3
International journal of colorectal disease · 2020
ISIlan Seth Weisberg
PMID: 33025103DOISenior author6 citations

32

3

2 studies

PI
A Pragmatic Approach to Pruritus Screening: A Descriptive Observational Study Using a Simplified Clinical Protocol
New York Presbyterian Brooklyn Methodist Hospital · OPEN TO ACCRUAL (as of 2025)
PI
Phase 3, Randomized, Controlled, Open-label Study to Compare the Efficacy and Safety of Bemnifosbuvir-Ruzasvir Fixed-dose Combination (BEM/RZR FDC) Versus Sofosbuvir-Velpatasvir Fixed-dose Combination (SOF/VEL FDC) in Subjects With Chronic Hepatitis C Virus (HCV) Infection
PHASE3 · Atea Pharmaceuticals, Inc. · OPEN TO ACCRUAL (as of 2025)
HEPATITIS C VIRUS CHRONIC INFECTION
NCT06868264

Completed & closed trials (1)

PI
IDEAL: A 52-week, Double-blind, Placebo-controlled, Randomized, Phase 3 Study Intended to Determine the Effects of Seladelpar on Normalization of Alkaline Phosphatase Levels in Subjects With Primary Biliary Cholangitis (PBC) and an Incomplete Response or Intolerance to Ursodeoxycholic Acid (UDCA)
PHASE3 · Gilead Sciences, Inc. · IRB STUDY CLOSURE (as of 2025)
Primary Biliary Cholangitis
NCT06060665

1

Gilead Sciences, Inc. · Ipsen Bioscience · Madrigal Pharmaceuticals, Inc.